CA-DEBIOPHARM
MedaSystems, a pioneer in software to provide access to pre-approval medicine, is pleased to announce additional funding from Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling patients to access novel treatments sooner. The investment adds to a growing list of prominent digital health investors in Europe and the United States, including Nina Capital and Young Sohn, a co-founder of Veeva Systems. The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process.
“We see significant synergies between MedaSystems and Debiopharm Innovation Fund. Our mutual dedication to building new approaches to pharmaceutical drug development and patient care will help bring promising pre-approval medicine to patients around the world, faster and more equitably. This funding supports our goal of making life-saving treatments more easily available to patients and physicians while advancing research and development of new therapies,” said Fiona Smythe, CEO of MedaSystems.
MedaSystems' SaaS platform facilitates the rapid processing of treatment inquiries and introduces new data capture capabilities, streamlining treatment for patients with unmet medical needs and aiding in collecting real-world data (RWD) for regulatory submissions. The platform is a vital link that ensures smooth collaboration among key partners in situations requiring pre-approval access. Physicians can swiftly manage patient requests and oversee the entire process in-app, working seamlessly with their teams and pharmacists. Pharmaceutical companies can integrate external partners like contract research organizations (CROs), guaranteeing effective communication, integrated services, and the quick shipment of treatment.
"Debiopharm Innovation Fund is committed to breaking down barriers in healthcare and promoting patient-centered solutions. Our investment in MedaSystems aligns perfectly with our dedication to innovation and the power of digital health technology in transforming patient outcomes. We believe their visionary approach to simplifying pre-approval access will play a key role in accelerating the delivery of life-saving treatments around the world. Together, we look forward to crafting a future where every patient has timely access to the most promising therapies." said Vincent Lepreux, Investment Principal at Debiopharm Innovation Fund.
About MedaSystems
MedaSystems is the leading developer of software that streamlines the handling of requests for experimental therapies from healthcare providers, supporting both Expanded Access and Post-Trial Access. MedaSystems' secure and GxP compliant application acts as a centralized environment, connecting physicians and pharmaceutical companies to facilitate global patient access to investigational therapies. By enabling the tracking and management of inquiries and data collection from these programs, MedaSystems transforms communications with clinicians into true partnerships, significantly reducing time and frustration for both parties involved.
About Debiopharm Innovation Fund
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides funding and guidance for companies with an ambition to improve the patient journey and transform pharmaceutical R&D. Since 2017, Debiopharm has invested in 15 AI and digital health companies, typically leading the investment rounds. As of September 2023, Debiopharm Innovation Fund is expanding its footprint through a new Seed financing activity.
For more information, please visit www.debiopharm.com/innovation-fund/
To learn more about investment criteria visit https://www.debiopharm.com/innovation-fund/approach/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109101056/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corona Cero Brings Golden Moments to the Mountains of Milano Cortina 20265.11.2025 10:30:00 CET | Press release
First-ever no-alcohol beer sponsor of Olympic Winter Games celebrates “For Every Golden Moment” platform with consumers globally As the 100-day countdown to the Olympic Winter Games continues, and in a year the global Corona brand is celebrating its 100th anniversary, Corona Cero is officially set to bring golden moments to the slopes of Milano Cortina 2026. As the first no-alcohol beer sponsor of the Winter Olympics, the brand is revving up its “For Every Golden Moment” global platform to invite consumers to celebrate every golden moment any time, any season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105994873/en/ Corona Cero's "For Every Golden Moment" Olympic Winter Games What began at the Olympic Games Paris 2024, Corona Cero’s Olympics partnership reinforces that beer and sports are better together by offering consumers more choices for any occasion. Corona Cero’s role reflects AB InBev and the International Oly
Nissan and Infobip Achieve 200% Increase in Engagement with AI-Driven WhatsApp Campaign5.11.2025 10:00:00 CET | Press release
AI-powered voice game sets new standard for digital marketing Nissan has redefined customer engagement by partnering with global cloud communications platform Infobip to pioneer a first-of-its-kind Agentic AI campaign. Nissan Kingdom of Saudi Arabia (KSA) leveraged Infobip’s newly launched Conversational AI Gamification, an AI-powered toolset that enables playful, immersive experiences across messaging channels. The marketing campaign utilized Infobip's Vocalize feature, an AI-powered voice game where users competed to win a brand-new Nissan Magnite. Participants used their voices to match an audio waveform to the outline of a car, directly within WhatsApp. This innovative approach transformed lead generation into an engaging competition, driving user participation and brand interaction. For Nissan KSA, the campaign enhanced brand awareness, increased engagement time, simplified lead acquisition, and stronger brand affinity. The innovative format also provided a cost-effective acquisit
NHOA Energy Commissions a 50 MWh Energy Storage System in Sicily5.11.2025 08:45:00 CET | Press release
The Vicari BESS, supplied on a turnkey EPC basis, integrates advanced storage technologies with two of ERG’s onshore wind farms, strengthening Sicily’s role in Italy’s energy transition NHOA Energy, a global provider of utility-scale energy storage systems, announces the commissioning of a 50 MWh Battery Energy Storage System (BESS) in Vicari, Sicily. Developed for ERG, a leading international independent renewable power producer, this project marks a major milestone in the deployment of large-scale storage systems supporting grid stability and renewable energy integration. Located at ERG’s substation connected to the Vicari and Roccapalumba wind farms, the system has a power capacity of 12.5 MW and a nominal storage capacity of 50 MWh, enabling it to store renewable energy for up to four hours. Fully designed, built, and commissioned by NHOA Energy as both BESS supplier and EPC (Engineering, Procurement and Construction) contractor, the project integrates proprietary Power Conversion
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile5.11.2025 07:00:00 CET | Press release
This approval is based on results showing the safety and effectiveness of Restylane Lyft in enhancing the chin profile, with high patient satisfaction and long-lasting results1,2 Restylane Lyft is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across diverse patient types1,2 Galderma’s Restylane portfolio, including Restylane Lyft, is supported by decades of clinical evidence and real patient experiences with over 77 million treatments delivered worldwide3,4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocainefor augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.2 Restylane Lyft is a versatile HA injectable with over 20 years of worldwide safety data, which is also
The Estée Lauder Companies Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders5.11.2025 02:08:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announces the pricing of the previously announced registered public offering (the “Offering”) of the Company’s Class A Common Stock, par value $.01 per share, by trusts affiliated with descendants of Leonard A. Lauder (the “Selling Stockholders”) at a price to the public of $90 per share. The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Class A Common Stock in the Offering and will not receive any proceeds from the Offering. The Offering is expected to close on November 6, 2025, subject to the satisfaction of customary closing conditions. The Selling Stockholders intend to use the proceeds of the Offering to assist with the settlement of Leonard A. Lauder’s estate, including to satisfy certain estate obligations such as estate taxes, debts and administration expenses. Based on shares outstanding as of October 23, 2025, following completion of the offering, members of th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom